Companies: 10,795·Total market cap: $144.5T
Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc.

AKBANASDAQHealthcare● Active
$0.94
$-0.04(-3.61%)
Market Cap$250901706
P/E Ratio
52W High$4.079
52W Low$0.875
Overview

Akebia Therapeutics, Inc. (AKBA) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · AKBA · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-0.08akba eps ttm · akba earnings per shareEarnings history
PE Ratio (TTM)akba pe ratio ttm · akba price to earningsPE Ratio deep dive
Revenue (TTM)$232.4Makba revenue ttm · akba annual revenueFull revenue history
Dividend YieldNo Dividenddoes akba pay dividends · akba dividend yieldDividend history
Shares Outstanding257.2Makba shares outstanding · akba floatShares outstanding history
Next EarningsAug 6, 2026Est.akba earnings date · akba next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$236.2M▲ +47.46% YoY
202320242025
akebia therapeutics, inc. revenue · akba revenue 2025
FY 2025Net Income-$5.3M▲ +92.30% YoY
202320242025
akebia therapeutics, inc. net income · akba profit 2025
FY 2025EPS$-0.02▲ +93.70% YoY
202320242025
akba eps · akebia therapeutics, inc. earnings per share 2025
TTM:Revenue: $232.4MNet Income: -$20.5MEPS: $-0.08View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy11 analystsis akba a buy · akba analyst rating
Strong Buy
0
Buy
7
Hold
3
Sell
1
Strong Sell
0
12-Month Price Target
$4.00Low
$0.94Current
$4.00Avg Target327.67% upside
$4.00High
akba price target · akba 12 month forecast

Total: 11 · Buy rate: 63.6%

The AKBA analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +327.67% upside from the current price of $0.94.

Stock Performance

Full History
1D-3.61%
1W-0.12%
1M-19.37%
3M-26.35%
YTD-41.91%
1Y-75.58%
5Y-74.02%

About Akebia Therapeutics, Inc.

CEOJohn Butler
IPO DateMar 20, 2014
Employees181
CountryUS
Websiteakebia.com

Akebia Therapeutics, Inc. a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational p…

what is akebia therapeutics, inc. · akba stock overview · akebia therapeutics, inc. company profile · who is akebia therapeutics, inc. ceo · akba NASDAQ · akebia therapeutics, inc. headquarters · akebia therapeutics, inc. business segments

About Stock Overview & Key Data

Akebia Therapeutics, Inc. (AKBA) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Mar 20, 2014. As of the latest trading session, AKBA stock price is $0.94, with a market capitalization of $250.9M. The stock has returned -75.58% over the past 12 months and -41.91% year-to-date.

According to 11 Wall Street analysts, the consensus rating for Akebia Therapeutics, Inc. stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2025, Akebia Therapeutics, Inc. reported revenue of $236.2M and net income of -$5.3M. For detailed data — including Akebia Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Akebia Therapeutics, Inc. (AKBA) stock price is $0.94. The stock is traded on NASDAQ under the ticker symbol AKBA. The 52-week range is $0.88 – $4.08.

AKBA stock priceAKBA quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice